# US 2015/0105276 A1 · Blood-based gene detection of non-small cell lung cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105276 A1
- Document ID: US20150105276A1
- Status: Published application
- Kind: A1
- Application number: 14/339,896
- Filed: 2014-07-24
- Published: 2015-04-16
- Earliest claimed: 2011-05-02
- Applicants: Rheinische Friedrich-Wilhelms-Universitat Bonn; Universitat Zu Koln
- Inventors: Andrea HOFMANN; Joachim L. Schultze; Andrea Staratschek-Jox; Jurgen Wolf; Thomas Zander
- Web page: https://patentgrep.com/patent/US20150105276A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention provides a method for early detection of non-small cell lung cancer based on the abundance of RNAs from blood samples as well as diagnostic tools such as kits and arrays suitable for such method.

## Claims

### Claim 1

A method for the detection of non-small cell lung cancer (NSCLC) in a human individual based on RNA obtained from a blood sample obtained from the individual, comprising:
determining the abundance of at least 5 RNAs in the sample that are chosen from the RNAs listed in Table 2, and
concluding based on the measured abundance whether the patient has NSCLC.

### Claim 2 (depends on 1)

The method of claim 1, wherein the abundance of at least 7, or of at least 11 RNAs that are chosen from the RNAs listed in Table 2 is determined.

### Claim 3 (depends on 1)

The method of claim 1, wherein
concluding comprises classifying the sample as being from a healthy individual or from an individual having NSCLC based on the specific difference of the abundance of the at least 5 RNAs in healthy individuals versus the abundance of the at least 5 RNAs in individuals with NSCLC.

### Claim 4 (depends on 3)

The method of claim 3, wherein the classifying is achieved by applying a Support Vector Machines (SVM), a random forest method, or a K-nearest neighbor method.

### Claim 5 (depends on 1)

The method of claim 1, which comprises determining the abundance of the RNAs specified in FIG. 2B.

### Claim 6 (depends on 1)

The method of claim 1, wherein the abundance of the RNAs in the sample are increased or decreased as shown in Table 2.

### Claim 7 (depends on 6)

The method of claim 6, wherein an increase of the abundance provides for a change of >1.1, >1.2, or >1.3, and a decrease of the expression provides for a change <0.9, <0.8, or <0.7 relative to the respective expression in a healthy individual.

### Claim 8 (depends on 1)

The method of claim 1, wherein the abundance is determined with an RNA hybridization assay, preferably with a solid phase microarray, a real-time polymerase chain reaction, or sequencing.

### Claim 9 (depends on 1)

The method of claim 1, wherein the abundance is determined through a hybridization with probes for determining the abundance of the at least 5 RNAs of Table 2.

### Claim 10 (depends on 9)

The method of claim 9, wherein said probes comprise 15 to 150, preferably 30 to 70 consecutive nucleotides with a reverse complementary sequence to the at least 5 RNAs whose abundance is to be determined.

### Claim 11

A microarray for the detection of NSCLC comprising probes for detecting at least 5, or at least 7, or at least 11 RNAs that are chosen from the RNAs listed in Table 2.

### Claim 12 (depends on 11)

Use of a microarray of claim 11 for the detection of non-small cell lung cancer (NSCLC) in a human individual based on RNA obtained from a blood sample obtained from the individual, preferably determining the abundance of at least 5 RNAs in the sample that are chosen from the RNAs listed in Table 2.

### Claim 13

A kit for the detection of NSCLC, comprising means for determining the abundance of at least 5 RNAs in the sample that are chosen from the RNAs listed in Table 2.

### Claim 14 (depends on 13)

The kit of claim 13, which comprises
probes comprising 15 to 150, preferably 30 to 70 consecutive nucleotides with a reverse complementary sequence to the at least 5 RNAs whose abundance is to be determined, or
a microarray comprising probes with a reverse complementary sequence to the at least 5 RNAs whose abundance is to be determined.

### Claim 15 (depends on 13)

The kit of claim 13, which further comprises a mixture of at least 5 of the RNAs of table 2 in a given amount for use as a standard.
